In a significant stride towards ethical biomedical advancements, Brisbane-based biotech company Gelomics has raised $2.2 million in a pre-seed funding round. This substantial investment will propel the company’s efforts in developing animal-free medical research models, aiming to revolutionize the field of drug testing and disease research.
Company Background
Founded in 2018, Gelomics is dedicated to transforming biomedical research by eliminating the need for animal models. The company specializes in creating advanced 3D cell culture technologies, such as the LunaGel
extracellular matrix system. This technology enables more accurate and reproducible research by providing tunable mechanical properties for 3D cell and organoid cultures.
